Arlington, Massachusetts-based Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) announced the pricing of a USD 66 million public offering of common stock and pre-funded warrants, with proceeds intended to advance its small molecule platform targeting nonsense mutations — a class of genetic defects that account for roughly 10%–15% of all inherited disease cases. The offering coincides with the company's uplisting to the Nasdaq Capital Market, a structural step that broadens access to institutional investors and provides a more liquid trading venue for ELOX stock.
The offering comprises 2,975,000 shares of common stock priced at USD 11.00 per share and pre-funded warrants to purchase up to 3,025,000 shares at USD 10.99 per warrant, with an exercise price of USD 0.01 per share. All securities are being sold by Eloxx, with no secondary component. Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers, with LifeSci Capital serving as passive bookrunner. The Eloxx USD 66 million offering was expected to close on June 10, 2026, subject to customary closing conditions.
Company overview and pipeline
Eloxx is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations. In cells carrying a nonsense mutation, the ribosome encounters a premature stop codon and terminates protein synthesis early, producing a truncated, typically nonfunctional protein. Eloxx's compounds are designed to allow the ribosome to read through these aberrant stop codons and generate full-length functional protein, potentially addressing the root cause of disease rather than managing downstream symptoms.
The company's lead clinical asset is ELX-02, a small molecule aminoglycoside analogue being developed for rare genetic diseases caused by nonsense mutations, including currently recruiting Phase II trials for cystic fibrosis. ELX-02 has received Orphan Drug Designation from the US FDA for the treatment of Alport Syndrome, a progressive rare kidney disease caused by mutations in genes encoding type IV collagen. The designation provides Eloxx with potential market exclusivity benefits and reduced regulatory fees upon approval.